Pentose lactobacillus plantarum yn-02, products prepared therefrom, and uses thereof

Abstract

The present application provides a kind of pentose lactobacillus YN-02 and product and application prepared from it, belong to biological medicine technical field, the pentose lactobacillus YN-02 is preserved in China typical culture collection on October 22, 2024, and the preservation number is CCTCC NO.M20242300;The gene sequence of 16srRNA of the pentose lactobacillus YN-02 is as shown in SEQ ID NO.1.The present application uses the above-mentioned pentose lactobacillus YN-02 and product and application prepared from it, has significant effect in anti-listeria monocytogenes, salmonella enteritidis, escherichia coli, staphylococcus aureus, salmonella typhimurium infection.

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a Lactobacillus pentosus YN-02 and products prepared therefrom and applications thereof. Background Art

[0002] Escherichia coli, a short, Gram-negative bacillus, is widely distributed in the natural environment and naturally lives in the intestines of humans and animals. Under normal circumstances, E. coli in the intestines are beneficial to humans, helping the body synthesize vitamin K and some B vitamins. However, some E. coli are pathogenic, causing symptoms such as intestinal infections, diarrhea, and vomiting. Severe infections can even lead to diseases such as hemorrhagic enterocolitis.

[0003] Lactic acid bacteria are a type of bacteria that metabolize carbohydrates and produce large amounts of lactic acid. They are widely distributed in nature and are diverse in species. The vast majority of these bacteria are closely associated with human life and are generally recognized as safe (GRAS). During their metabolism, lactic acid bacteria produce a variety of natural antibacterial substances, including bacteriocins, organic acids, diacetyl, and hydrogen peroxide. These substances constitute a probiotic community that is present in the gastrointestinal tract of animals.

[0004] The antibacterial substances produced by lactic acid bacteria not only preserve the flavor of food but also effectively inhibit the growth of pathogens and spoilage bacteria, thereby extending the shelf life and quality assurance period of food. Among these metabolites, bacteriocins produced by lactic acid bacteria play a major role. Bacteriocins are heat-stable and easily degraded by proteases in the human digestive tract. They are also non-toxic and less likely to develop drug resistance. Therefore, bacteriocins hold broad application prospects in food storage, animal husbandry, and as food preservatives.

[0005] However, it's worth noting that despite the enormous potential of lactic acid bacteria across multiple fields, research on certain specific lactic acid bacteria species remains relatively scarce. For example, the specific mechanisms of action and efficacy of Lactobacillus pentosus YN-02, a potentially valuable lactic acid bacteria strain, in food preservation and health promotion remain largely unexplored. Summary of the Invention

[0006] The present invention aims to provide a lactobacillus pentosus strain YN-02 and products and applications prepared therefrom, which have significant effects in resisting infections by Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

[0007] To achieve the above object, the present invention provides a lactobacillus pentosus plant bacillus YN-02, which was deposited in the China Center for Type Culture Collection on October 22, 2024, with a deposit number of CCTCCNO.M20242300; its Latin name is Lactiplantibacillus pentosus ;

[0008] The gene sequence of 16srRNA of the Lactobacillus pentosus YN-02 is shown in SEQ ID NO.1.

[0009] The present invention also provides a medicine comprising the above-mentioned Lactobacillus pentosus YN-02, which has the function of resisting infections by Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

[0010] Preferably, the medicine contains live and / or inactivated bacteria of Lactobacillus pentosus YN-02, wherein the number of live bacteria of Lactobacillus pentosus YN-02 is 1×10 9 CFU / mL.

[0011] The present invention also provides a use of the above-mentioned Lactobacillus pentosus YN-02 in the preparation of an antibacterial agent, wherein the antibacterial agent is an antibacterial agent against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

[0012] Therefore, the present invention adopts the above-mentioned Lactobacillus pentosus YN-02 and the products and applications prepared therefrom, and the beneficial technical effects are as follows:

[0013] (1) The present invention is based on Lactobacillus pentosus YN-02, and can develop medicines that can alleviate infections such as Escherichia coli.

[0014] (2) Lactobacillus pentosus YN-02 can regulate intestinal flora, restore metabolic disorders, thereby improving intestinal homeostasis and enhancing the body's immune function. It has a significant effect in resisting infections such as Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 This is the phylogenetic tree of Lactobacillus pentosus YN-02;

[0016] Figure 2 Annotation of the genes of Lactobacillus pentosus YN-02;

[0017] Figure 3 Annotation for carbohydrate-active enzymes of Lactobacillus pentosus YN-02;

[0018] Figure 4The antibacterial activity of Lactobacillus pentosus YN-02;

[0019] Figure 5 The effect of Lactobacillus pentosus YN-02 on the potassium ion concentration inside and outside the Escherichia coli cells;

[0020] Figure 6 The effect of Lactobacillus pentosus YN-02 on the protein content inside and outside Escherichia coli cells;

[0021] Figure 7 The effect of Lactobacillus pentosus YN-02 on the ATPase concentration of Escherichia coli;

[0022] Figure 8 The effect of Lactobacillus pentosus YN-02 on the intracellular and extracellular concentrations of alkaline phosphatase in Escherichia coli;

[0023] Figure 9 The effect of Lactobacillus pentosus YN-02 on Escherichia coli biofilm;

[0024] Figure 10 This is a diagram of the organ degeneration degree and overall health of mice; Figure 10 (a) is the cardiac index diagram of mice; Figure 10 (b) is the graph of mouse lung index and spleen index; Figure 10 (c) is the mouse kidney index diagram;

[0025] Figure 11 is the intestinal villus height and crypt depth map; Figure 11 (a) is a bar graph of intestinal villus height and crypt depth; Figure 11 (b) is the ratio V / C diagram of mouse intestinal villus height (V) and crypt depth (C);

[0026] Figure 12 Figure 2 is a diagram of apoptosis and proliferation of intestinal epithelial cells; Figure 12 (a) is the cell density and positive rate diagram; Figure 12 (b) in the figure is the average optical density map. DETAILED DESCRIPTION

[0027] The technical solution of the present invention is further described below with reference to the accompanying drawings and embodiments.

[0028] Unless otherwise defined, technical or scientific terms used in the present invention shall have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.

[0029] Example 1

[0030] Isolation and screening of Lactobacillus pentosus YN-02.

[0031] Collect fresh yogurt and inoculate it into MRS broth (solid) and incubate at 37°C for 24-48 hours to enrich the lactic acid bacteria. Use the streak plate method to inoculate the enriched lactic acid bacteria onto MRS agar and incubate at 37°C for 24-48 hours. Single colonies are then picked for purification.

[0032] Initial screening is performed using the Oxford cup method or paper disc method. Known indicator bacteria (such as common pathogens like Escherichia coli and Staphylococcus aureus) are spread onto a solid MRS broth plate. An Oxford cup or a paper disc containing a culture medium of a yogurt strain is then placed on the plate. After a period of incubation, if the yogurt strain produces antibacterial substances, a distinct zone of inhibition will form around the Oxford cup or paper disc. The diameter of the inhibition zone is measured to preliminarily identify yogurt strains with antibacterial activity. Strains identified in the initial screening are inoculated into liquid MRS broth for fermentation, and the fermentation broth is collected. The fermentation broth is then co-cultured with the indicator bacteria, and the growth of the indicator bacteria is measured, for example, by measuring absorbance to determine the degree of growth inhibition. Compared to the initial screening, the secondary screening method provides a more accurate assessment of the antibacterial ability and stability of the strains.

[0033] The formula of MRS broth medium (solid) is as follows: soy peptone 10 g, beef extract 5 g, yeast powder 4 g, glucose 20 g, Tween-80 1 mL, disodium hydrogen phosphate 2 g, anhydrous sodium acetate 5 g, triamcinol citrate 2 g, manganese sulfate 0.02 g, magnesium sulfate 0.1 g, agar powder 15 g, distilled water to 1 L, adjust the initial pH to 6.20, and sterilize at 121°C for 15 min.

[0034] The formula of MRS broth medium (liquid) is as follows: soy peptone 10 g, beef extract 5 g, yeast powder 4 g, glucose 20 g, Tween-80 1 mL, disodium hydrogen phosphate 2 g, anhydrous sodium acetate 5 g, triamcinol citrate 2 g, manganese sulfate 0.02 g, magnesium sulfate 0.1 g, and distilled water to 1 L. Adjust the initial pH to 6.20 and sterilize at 121°C for 15 min.

[0035] Morphological observations of the antibacterial strains identified in the rescreening were performed, including colony morphology (e.g., colony size, shape, color, and margins) and bacterial morphology (microscopic observation of cell shape, size, and arrangement). These observations were compared with known morphological characteristics of lactic acid bacteria to preliminarily determine the strain's type. A series of physiological and biochemical tests (commonly used in the field) were then conducted to further determine the strain's physiological and biochemical characteristics. These characteristics were then compared with a database of known physiological and biochemical characteristics of lactic acid bacteria to accurately identify the strain.

[0036] Molecular biological identification.

[0037] The genomic DNA of the strain was extracted, and its 16srRNA gene and other specific gene fragments were amplified using PCR technology and sequenced. The molecular sequence was compared with the NCBI database blastn, confirming that YN-02 was a lactobacillus pentosus. The phylogenetic tree of YN-02 is shown in Figure 2. Figure 1 shown.

[0038] The complete genome of Lactobacillus pentosus YN-02 was sequenced using the Illumina HiSeq platform. After assembly and alignment, the genome was 2,019,473 bp in length, with a G+C content of 42.31%, containing one plasmid, and the chromosomal genome contained 2,071 coding genes.

[0039] Test for resistance to gastrointestinal fluids and bile salts.

[0040] The survival rate of Lactobacillus pentosus was 98% at pH 2.0. When Lactobacillus pentosus was cultured in simulated gastric fluid (pH 2.5) at a constant temperature (37°C) for 2-4 hours, its survival rate reached 96%. When transferred to simulated intestinal fluid (pH 8.0) and cultured at 37°C for 3 hours, the survival rate reached 92%. When Lactobacillus pentosus was cultured in a medium containing a certain concentration of bile salts (0.3%) and also at 37°C, the survival rate reached 94.5%. This demonstrates that Lactobacillus pentosus YN-02 possesses excellent resistance to gastrointestinal fluid and bile salts, allowing it to survive in the human gastrointestinal environment.

[0041] Example 2

[0042] Functional gene characteristics of Lactobacillus pentosus YN-02.

[0043] The KEGG database was used to perform functional annotation on the entire genome of Lactobacillus pentosus YN-02. KEGG is a specialized database for molecular-level comparison and analysis of bacterial genes and metabolic pathways. It enables molecular-level exploration of bacteria and studies the relationships between functional genes and biomolecules in various biological pathways. The KEGG database categorizes microbial biological pathways into six major categories: metabolism, genetic information processing, environmental information processing, cellular processes, organismal systems, and human diseases.

[0044] Figure 2Detailed annotation results were presented. Lactobacillus pentosus YN-02 was annotated with 1,873 functional genes using KEGG. The largest function was metabolism, while the smallest was cellular processes. Metabolic processes included 175 genes related to carbohydrate metabolism, 102 genes related to membrane transport, 76 genes related to nucleotide metabolism, and 67 genes related to cofactor and vitamin metabolism, indicating that the strain has strong carbohydrate, nucleotide, and vitamin metabolism capabilities.

[0045] The Carbohydrate Active Enzyme Database (CAZy) is a database that compares and annotates complex enzymes that synthesize or utilize carbohydrates and other sugars in bacteria. The CAZy database divides carbohydrate active enzymes into six categories: glycoside hydrolases (GH), glycosyltransferases (GT), polysaccharide lyases (PL), carbohydrate esterases (CE), carbohydrate binding modules (CM), and auxiliary oxidoreductases (AA). Figure 3 As shown, 64 genes encoding carbohydrate-active enzymes were successfully annotated for Lactobacillus pentosus YN-02 using the CAZy database, and were divided into four protein families based on the amino acid sequence similarity in the encoded protein domains, including 5 auxiliary oxidoreductase (AA) genes, 11 carbohydrate-binding module (CM) genes, 30 glycoside hydrolase (GH) genes, and 18 glycosyltransferase (GT) genes.

[0046] The tolerance-related functional genes of Lactobacillus pentosus YN-02 were annotated, and 8 acid tolerance-related genes were annotated ( glmU 、 ygjK 、 celA 、 celB 、 celC 、 bglA 、 licR 、 crr ); 1 bile salt tolerance-related gene ( rpiU ); 5 antibacterial related genes ( FabG 、 SrtA 、 rsgA 、 opuBD 、 OpuA ); 3 adhesion-related genes ( thiN 、 purD 、 gcvH ).

[0047] Genes related to antibacterial function were detected in the genome of Lactobacillus pentosus YN-02 and annotated. The specific genes are shown in Table 1.

[0048] Table 1 Genes related to antibacterial function of Lactobacillus pentosus YN-02

[0049]

[0050] Example 3

[0051] Antibacterial activity of Lactobacillus pentosus YN-02.

[0052] Preparation of fermentation supernatant and indicator bacteria of Lactobacillus pentosus YN-02.

[0053] Each test strain was inoculated into MRS liquid medium at a 2% volume fraction and fermented at 37°C for 24 hours. The supernatant was collected by centrifugation (8000 rpm for 10 minutes), filtered through a 0.22 μm microporous filter, and refrigerated at 4°C until use. Each indicator bacterium was inoculated into LB broth at a 2% volume fraction and cultured at 37°C for 24 hours until the second generation was reached. The fungus was inoculated onto a PDA slant medium and cultured in a 28°C incubator for 4 days. A certain amount of sterile saline was then added, and spores were scraped from the slant. The spores were shaken, and the sterile saline containing the fungus spores was filtered through sterile gauze to remove mycelial debris. The spore suspension concentration was adjusted to approximately 105 spores / mL and refrigerated at 4°C until use.

[0054] Determination of antibacterial activity of fermentation supernatant of Lactobacillus pentosus YN-02.

[0055] like Figure 4 As shown, inhibition assays of Lactobacillus pentosus YN-02 revealed antibacterial activity against all tested strains at a concentration of 512 μM, with inhibition rates exceeding 90%. Inhibition rates against Listeria monocytogenes, Salmonella Enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium were 98.93%, 97.45%, 93.79%, 99.38%, and 97.35%, respectively. This study validated Lactobacillus pentosus YN-02 as a strain with high antibacterial activity against a wide range of bacteria. It is believed that the antibacterial active substances in the fermentation supernatant of Lactobacillus pentosus YN-02 have a broad inhibitory range, suggesting potential for future development and application.

[0056] The antibacterial mechanism of Lactobacillus pentosus YN-02 is explained below by its antibacterial effect on Escherichia coli.

[0057] (1) Effect of Lactobacillus pentosus YN-02 on the permeability of Escherichia coli cell membrane.

[0058] Effect of Lactobacillus pentosus YN-02 on potassium ion concentration inside and outside the bacteria.

[0059] There is a concentration difference between potassium ions inside and outside bacterial cells. The permeability of the cell membrane to potassium ions is crucial for maintaining this concentration difference and the normal physiological function of the cell. The concentration of potassium ions released from Escherichia coli after being treated with Lactobacillus pentosus YN-02 was investigated.Figure 5 As shown, the intracellular potassium concentration in normally growing E. coli cells is 1.76 mg / L; after treatment with Lactobacillus pentosus YN-02, the intracellular potassium concentration increased by 5.94 mg / L. This indicates that Lactobacillus pentosus YN-02 increases the permeability of the E. coli cell membrane, leading to the release of more potassium ions from the cells.

[0060] Effect of Lactobacillus pentosus YN-02 on protein content inside and outside the bacteria.

[0061] Changes in protein content inside and outside bacteria can reflect the growth status and environmental adaptability of bacteria. If the protein content in bacteria decreases, it may mean that the growth and reproduction of bacteria are inhibited, or that the protein produced by bacteria is consumed or degraded by other organisms or environmental factors. Figure 6 As shown, the intracellular protein concentrations of normally grown E. coli and treated E. coli were 4.42 and 3.08 mg / mL, respectively, accounting for 72% and 56% of the total protein content, respectively. The concentrations of leaked protein in the supernatant of the control and treated E. coli were 1.64 and 2.44 mg / mL, respectively, accounting for 28% and 34% of the total protein content. These results indicate that after treatment with Lactobacillus pentosus YN-02, the cell membrane is disrupted, allowing a large amount of protein to leak from the bacterial cells.

[0062] (2) Effects of Lactobacillus pentosus YN-02 on bacterial metabolic enzymes.

[0063] Effect of Lactobacillus pentosus YN-02 on bacterial ATPase concentration.

[0064] ATPase is mainly involved in energy conversion and ion transport, and is a key enzyme in the production of energy in bacteria. When cells are damaged or die, the ATP content in the bacterial cells will drop rapidly, so the ATP content can reflect the survival status of the cells. Figure 7 As shown, compared to the control group, the ATPase concentration of E. coli treated with Lactobacillus pentosus YN-02 gradually decreased significantly (p < 0.05). This may mean that YN-02 affects the bacterial energy metabolism, affecting its vital activities, and thus inhibiting or killing the bacteria. Therefore, Lactobacillus pentosus YN-02 can inhibit the expression and activity of ATPase in bacterial cells.

[0065] Effect of Lactobacillus pentosus YN-02 on bacterial alkaline phosphatase.

[0066] Alkaline phosphatase plays an important role in bacterial physiological processes such as energy metabolism, cell wall synthesis and material transport. Figure 8Compared to the E. coli control group, after treatment with Lactobacillus pentosus YN-02, the percentage of intracellular alkaline enzyme decreased significantly from 84% to 14%, while the percentage of extracellular alkaline enzyme increased significantly from 16% to 86%. This indicates that Lactobacillus pentosus YN-02 can inhibit the expression of alkaline phosphatase in bacterial cells.

[0067] (3) Effect of Lactobacillus pentosus YN-02 on bacterial biofilm formation.

[0068] Depend on Figure 9 As shown, Lactobacillus pentosus YN-02 achieved an inhibition rate of 88.4% against immature E. coli biofilms, demonstrating that Lactobacillus pentosus YN-02 effectively inhibits bacterial biofilms in the early stages of formation, thereby preventing further biofilm development. Lactobacillus pentosus YN-02 also exhibited strong inhibitory activity against mature biofilms, achieving an inhibition rate of 94.6% against mature E. coli biofilms. This demonstrates that Lactobacillus pentosus YN-02 not only prevents biofilm formation but also effectively destroys established biofilms, demonstrating its potential application in anti-biofilm therapy.

[0069] Therefore, Lactobacillus pentosus YN-02 inhibits the formation of Escherichia coli biofilm by destroying the integrity of the Escherichia coli cell membrane, enhancing the cell membrane permeability, affecting the intracellular and extracellular proteins and potassium ions, and changing the content and activity of metabolic enzymes such as ATPase and alkaline phosphatase, thereby achieving efficient sterilization of Escherichia coli.

[0070] Example 4

[0071] Therapeutic effect of Lactobacillus pentosus YN-02 on Escherichia coli-infected mice.

[0072] Experimental methods: In this example, changes in mouse body weight, survival rate, food intake, etc. were observed. These clinical symptoms and growth index changes can be used to preliminarily assess the health status of the mice. The effects of Lactobacillus pentosus YN-02 on the immune system and antioxidant system of the mice were then quantified by measuring the cytokines and antioxidant capacity of the mouse blood. The effects on intestinal pathological changes were then determined by HE staining and cell apoptosis detection of intestinal tissue, which intuitively reflected the therapeutic effect of Lactobacillus pentosus YN-02 on intestinal inflammation and damage. Finally, the analysis of intestinal microorganisms and metabolites can reveal the effects of Lactobacillus pentosus YN-02 on the intestinal microorganisms, metabolites and metabolic pathways of mice. Among them, the blank control group (CON, gavage with 0.2 mL of normal saline), the Escherichia coli model group (MOD, gavage with 1×10 8 coli), Lactobacillus pentosus YN-02-treated group (TMT, gavage 1×10 8 CFU Escherichia coli + oral gavage 1×108 CFU of Lactobacillus pentosus YN-02 powder), Lactobacillus pentosus YN-02 control group (PET, gavage 1×10 8 CFU Lactobacillus pentosus YN-02 bacterial powder).

[0073] Effects of Lactobacillus pentosus YN-02 on organ coefficients in mice infected with Escherichia coli.

[0074] The organ coefficient of mice can be used to evaluate the degree of organ degeneration and overall health of mice. Figure 10 As shown, the cardiac index in the MOD and TMT groups was lower than that in the CON group (p < 0.05), but the spleen, kidney, liver, and lung indices were higher. Comparing the data between the MOD and TMT groups, significant differences were observed, particularly in the spleen and cardiac indices. In summary, Lactobacillus pentosus YN-02 has a certain effect on restoring organ function and health in mice.

[0075] Improvement effect of Lactobacillus pentosus YN-02 on intestinal function in mice infected with Escherichia coli.

[0076] Intestinal villus height and crypt depth are important indicators of intestinal function. The V / C ratio is calculated based on the villus height (V) and crypt depth (C) of the mouse intestine. Figure 11 The CON group had significantly higher villus height than the MOD and TMT groups (p < 0.05), with the TMT group showing higher villus height than the MOD group. Crypt depth did not differ significantly between groups. The CON group had the highest value (V / C), followed by the TMT group and then the MOD group. In summary, Lactobacillus pentosus YN-02 can repair intestinal mucosal damage caused by E. coli and enhance digestion and absorption in mice.

[0077] Improvement effect of Lactobacillus pentosus YN-02 on intestinal cell apoptosis in mice infected with Escherichia coli.

[0078] The key factors in maintaining intestinal homeostasis are apoptosis and proliferation of intestinal epithelial cells. Figure 12 As shown, the MOD group had the highest positive rate, the highest number of apoptotic cells, and the highest cell density, indicating extensive apoptosis in the mouse colonic epithelium. The CON and TMT groups were next, with significantly fewer apoptotic cells than the MOD group. Finally, the PEP group had a positive rate of 0.35%, indicating no obvious signs of apoptosis in the mouse colonic epithelium. In summary, it is hypothesized that Lactobacillus pentosus YN-02 may improve intestinal function by inhibiting epithelial cell apoptosis.

[0079] Experimental Results: Animal experiments were conducted to investigate the therapeutic effects and in vivo antibacterial mechanisms of Lactobacillus pentosus YN-02 on mice infected with Escherichia coli. The mice were divided into four groups: a blank control, E. coli infection, L. pentosus YN-02 treatment, and a single-bacterium control. The results showed that E. coli infection caused lethargy, decreased appetite, weight loss, and altered organ function in the mice. Oral administration of L. pentosus YN-02 effectively alleviated these symptoms, restoring the mice to normal function. Furthermore, L. pentosus YN-02 promoted intestinal villus growth, reduced cell apoptosis, and alleviated intestinal damage. By regulating the microbiome, L. pentosus YN-02 restored the metabolic disturbances caused by E. coli infection. Therefore, L. pentosus YN-02 exhibited significant protective effects against E. coli infection in mice.

[0080] Therefore, the present invention adopts the above-mentioned Lactobacillus pentosus YN-02 and the products and applications prepared therefrom, which have significant effects against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

[0081] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention rather than to limit the same. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that they can still modify or replace the technical solutions of the present invention with equivalents, and these modifications or equivalent replacements cannot cause the modified technical solutions to deviate from the spirit and scope of the technical solutions of the present invention.

Claims

1. A Lactobacillus pentosus YN-02, characterized in that The lactobacillus pentosus plantarum YN-02 was deposited in the China Center for Type Culture Collection on October 22, 2024, with the deposit number CCTCC NO.M20242300; its Latin name is Lactiplantibacillus pentosus ; The gene sequence of 16srRNA of the Lactobacillus pentosus YN-02 is shown in SEQ ID NO.1; The lactobacillus pentosus YN-02 has an inhibitory effect on Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus, and Salmonella typhimurium.

2. A medicine comprising the Lactobacillus pentosus YN-02 according to claim 1, characterized in that: The medicine has the function of resisting infection by Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus and Salmonella typhimurium.

3. A medicine comprising Lactobacillus pentosus YN-02 according to claim 2, characterized in that: The medicine contains live and / or inactivated bacteria of Lactobacillus pentosus YN-02, wherein the number of live bacteria of Lactobacillus pentosus YN-02 is not less than 1×10 9 CFU / mL.

4. A use of the Lactobacillus pentosus YN-02 according to claim 1 in the preparation of an antibacterial agent, characterized in that: The antibacterial agent is an antibacterial agent against Listeria monocytogenes, Salmonella enteritidis, Escherichia coli, Staphylococcus aureus and Salmonella typhimurium.

Images